Eli Lilly announced its acquisition of Kelonia Therapeutics, a gene therapy company focused on cancer treatments, for up to $7 billion in cash. This marks the largest purchase of a venture-backed biotech startup in recent years, underscoring confidence in Kelonia’s promising genetic medicine pipeline, including a multiple myeloma treatment showing strong clinical results. Founded just four years ago with $50 million in initial funding, Kelonia has quickly advanced, partnering with Astellas Pharma’s subsidiary to develop immuno-oncology therapies. Its innovative platform offers a faster, simpler alternative to CAR T-cell therapies by reprogramming patients' T-cells internally to fight cancer. The deal includes $3.25 billion upfront and potential milestone payments up to $3.75 billion, surpassing recent high-value acquisitions of similar in vivo therapeutic startups by Lilly and others. This acquisition highlights a growing trend in the biotech sector valuing rapid innovation in gene and cell therapy development.
Your front desk often represents the first point of contact for patients, guests, and visitors alike—available 24/7 to handle appointment rescheduling, visitor check-ins, or inquiries. Yet, traditional receptionists face limits in managing simultaneous demands, risking missed calls and lost revenue opportunities.
Enter the AI receptionist: a sophisticated system driven by conversational AI and deep integrations with business platforms. These AI agents handle comprehensive front desk tasks smoothly—from booking and rescheduling appointments to greeting visitors, scanning documents, and even managing access control and services like coffee ordering.
AI receptionists come in two main types: voice-first systems that answer calls and manage scheduling round the clock without hold times, and digital human avatars stationed in lobbies or kiosks that interact face-to-face with in-person visitors.
They significantly reduce costs (by 40–60%), decrease no-show rates by 30%, and speed up visitor check-in processes by up to five times. Healthcare settings, office buildings, and hotels benefit immensely, with AI receptionists managing patient registrations, visitor flows, room bookings, and guest services efficiently.
Integrations with APIs allow these AI systems to control physical access, coordinate with HR directories, trigger security protocols, and even handle catering orders, effectively becoming the nerve center of the front-of-house operations.
Implementation is straightforward and swift, typically completed in weeks, involving discovery, system integration, persona customization, and rigorous testing. Continuous monitoring ensures ongoing improvement.
Businesses investing in AI receptionists today gain enhanced availability, scalability, and operational consistency that human-only front desks can't match.
A recent VentureBeat survey of 40 enterprise companies reveals that 72% claim to operate two or more primary AI platforms, exposing significant gaps in AI governance and security. The proliferation of AI platforms—from leaders like Microsoft Azure, Google, OpenAI, Anthropic, and other major software vendors—has led to operational sprawl without a unified strategy. This creates contradictions in control and security, as seen in examples like Mass General Brigham hospital system, which built custom solutions around large providers’ AI tools to address data privacy concerns.
The survey data highlights a governance paradox: although 56% of enterprises express confidence in detecting AI misbehavior, many lack systematic mechanisms and clear ownership of governance responsibilities. Vendor opacity and the absence of a single accountable team are among the biggest obstacles. Industry voices like Red Hat warn of "day-two" challenges, where initial ease of adoption masks the complexity and risk of vendor lock-in or unmanaged shadow AI projects.
Some enterprises adopt a flexible "dynamic defensive" approach, avoiding long-term commitments due to rapidly evolving vendor landscapes. Meanwhile, platform providers increasingly offer "managed agents" that consolidate more AI operations but risk deepening dependency and reducing oversight.
Security risk escalates as many enterprises rely on the very providers that generate AI risks to also secure their systems, creating a "security irony." In response, experts call for a centralized "control plane" or a "Dynatrace for AI"—a unified observability platform that enables end-to-end visibility and control, including a hard-stop "big red button" for emergency intervention. Enterprises need to formalize governance with independent oversight rather than depend solely on vendors, ensuring sustainable AI scaling amid evolving risks.
This innovative therapy harnesses mRNA technology to deliver personalized cancer treatment tailored to each patient's unique profile.
Carsten Eickhoff from the University of Tübingen examines challenges linked to the use of AI chatbots for addressing medical questions, highlighting concerns in their current application.
Cirrascale Cloud Services has expanded its partnership with Google Cloud to deliver the Gemini AI model in a fully private, on-premises appliance using Google Distributed Cloud. This innovative solution offers enterprises and government agencies the ability to run Gemini on dedicated hardware equipped with eight Nvidia GPUs, disconnected from the internet and Google's cloud. The Gemini model resides entirely in volatile memory, ensuring it vanishes when powered off and cannot be tampered with, providing unparalleled data security. With flexible licensing and deployment options, the product targets regulated sectors like finance, healthcare, and public sector research, addressing data sovereignty and security concerns. This move marks a significant shift from traditional cloud AI, bringing powerful frontier models into customers' own infrastructure and signaling the rise of private AI deployments.
Rising insurance costs and fresh transparency regulations are driving businesses to explore more affordable alternatives, including nontraditional health insurers and pharmacy benefit managers.
The UK government has confirmed that anonymized health records of 500,000 British volunteers from the UK Biobank project were found on sale through multiple listings on Alibaba, a Chinese e-commerce platform. Technology Minister Ian Murray informed the Commons that after collaboration with Chinese authorities and Alibaba, the listings were taken down. There is no evidence that any transactions occurred involving this sensitive data.
Eli Lilly is set to acquire Kelonia Therapeutics for $3.25 billion upfront, aiming to strengthen its oncology and genetic medicines pipeline beyond its existing GLP-1 offerings.
Claim Clarity highlights that workers’ compensation is a vital but often overlooked part of the healthcare system. Jamie LaPaglia, Founder and CEO, explains that despite its growing importance, workers' comp is frequently treated like standard healthcare. However, it operates under unique regulatory and operational conditions that require specialized attention. In this setting, specialized AI tools are playing an increasingly important role in improving the accuracy and effectiveness of decisions related to workers’ compensation claims.
